Trial Profile
The Efficacy Study of Neoadjuvant Xelox in Patients with Locally Advanced Lower Rectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- 01 Feb 2016 Status changed from active, no longer recruiting to completed, as per the published in the Anticancer Research.
- 01 Feb 2016 Results published in the Anticancer Research
- 02 Feb 2012 New trial record